Avience Biomedicals
Avience Biomedicals Limited is a medical consumable company dedicated to manufacturing of Vitro-Diagnostic (IVD) products and medical devices in Noida, Uttar Pradesh, India. In vitro diagnostics (IVDs) are tests that can detect disease, conditions and infections. In vitro simply means ‘in glass’, meaning these tests are typically conducted in test tubes and similar equipment, as opposed to in vivo tests, which are conducted in the body itself. In vitro tests can be done in laboratories, health care facilities or even in the home. The tests themselves can be performed on a variety of instruments ranging from small, handheld tests to complex laboratory instruments. Avience Biomedicals Limited commenced its journey by producing essential diagnostic kits like Viral Transport Media (VTM), Covid, Human Immunodeficiency Viruses (HIV), HBs AG,
High quality fundamentals with reasonable valuation
SME IPOs are higher risk, less liquid and more volatile than mainboard IPOs. Invest only after reading the offer document and understanding the risks.
Plain-English Summary✨
What does the company do?
Avience Biomedicals IPO is open for subscription with a price band of 196-208. The company is a medical consumable company dedicated to manufacturing of Vitro-Diagnostic (IVD) products and medical devices.
Why are investors interested?
The company has shown growth in revenue and profit after tax, but the debt to equity ratio is high. The EBITDA margin is strong, but more information on the company's products and services is needed.
What should beginners watch out for?
Some data points such as promoters' holding, company's products and services, and subscription data are missing or stale.
Key IPO Metrics
GMP Today
+69.7%
Total Subscription
Overall demand
Retail Subscription
Retail Queue
QIB Subscription
Institutional Queue
NII (HNI) Subscription
Non-Institutional
Anchor Book
Subscribed
SME Risk Radar
GYR Capital Market Maker
Merchant banker track record is not available.
Post-listing volume can be low. Trading takes place in large retail lots.
Top 5 customers account for more than 40% of revenues.
Scale of operations is relatively small, with minor audit flags.
Business Overview
About the Company
Avience Biomedicals Limited is a medical consumable company dedicated to manufacturing of Vitro-Diagnostic (IVD) products and medical devices in Noida, Uttar Pradesh, India. In vitro diagnostics (IVDs) are tests that can detect disease, conditions and infections. In vitro simply means ‘in glass’, meaning these tests are typically conducted in test tubes and similar equipment, as opposed to in vivo tests, which are conducted in the body itself. In vitro tests can be done in laboratories, health care facilities or even in the home. The tests themselves can be performed on a variety of instruments ranging from small, handheld tests to complex laboratory instruments. Avience Biomedicals Limited commenced its journey by producing essential diagnostic kits like Viral Transport Media (VTM), Covid, Human Immunodeficiency Viruses (HIV), HBs AG,
Industry
Healthcare
Business Segments
Objects of the Issue
Promoters
Promoters group
Whole-time Directors & Promoter group
Lead Managers
Registrar
TBAIssue & Valuation
Peer Snapshot (FY24)
| Company | P/E (x) | ROE (%) | Revenue CAGR (3Y) | EBITDA Margin (%) | Market Cap (₹ Cr) |
|---|---|---|---|---|---|
| Avience Biomedicals (IPO) | 14.61x | 20.13% | -7.5% | 24.7% | -- |
| Adeshwar Meditex | 19.53x | -- | -- | -- | ₹103.56 Cr |
| Amkay Products | 16.58x | -- | -- | -- | ₹45.495 Cr |
| Aprameya Engineering | 31.95x | -- | -- | -- | ₹9,843.33 Cr |
| Asarfi Hospital | 12.78x | -- | -- | -- | ₹106.05 Cr |
| Chemkart India | 12.37x | -- | -- | -- | ₹199.245 Cr |
| Clinitech Laboratory | 59.03x | -- | -- | -- | ₹965.88 Cr |
| Dr Lalchandani | 10x | -- | -- | -- | ₹3.855 Cr |
| Earkart Limited | 26.98x | -- | -- | -- | ₹64.65 Cr |
| Galaxy Medicare | 23.96x | -- | -- | -- | ₹58.8 Cr |
| Gian Life | 7.61x | -- | -- | -- | ₹10.74 Cr |
| Hemant Surgical | 12.28x | -- | -- | -- | ₹163.71 Cr |
| Influx Healthtech | 16.63x | -- | -- | -- | ₹157.275 Cr |
| KMS Medisurgi | 60x | -- | -- | -- | ₹11.22 Cr |
| Mohini Health | 11x | -- | -- | -- | ₹247.11 Cr |
| Powerhouse Fitness | 270x | -- | -- | -- | ₹5.745 Cr |
| Prevest Denpro | 13.55x | -- | -- | -- | ₹41.16 Cr |
| Q-Line Biotech | 20.68x | -- | -- | -- | ₹464.835 Cr |
| QMS Medical | 20.1x | -- | -- | -- | ₹219.48 Cr |
| Royal Sense | 23.69x | -- | -- | -- | ₹24.09 Cr |
| Transpact Enterprises | -- | -- | -- | -- | ₹0.255 Cr |
| Unihealth Consultancy | 26.56x | -- | -- | -- | ₹69.045 Cr |
| Vasa Denticity | 30.62x | -- | -- | -- | ₹174.555 Cr |
| Yash Optics | 23.74x | -- | -- | -- | ₹55.98 Cr |
Financials & Performance(Standalone)
Revenue (₹ Cr)
CAGR 32.1%PAT (₹ Cr)
CAGR 63.1%EBITDA Margin (%)
ImprovingROCE (%)
Healthy TrendROE (%)
ImprovingFinancial Quality
GoodGood / Improving metrics, margins and cash flows with comfortable leverage.
| Financial Year | Revenue (₹ Cr) | EBITDA Margin (%) | PAT (₹ Cr) | ROCE (%) | ROE (%) | Debt / Equity (x) |
|---|---|---|---|---|---|---|
| FY24 | ₹23.96 Cr | 18.57% | ₹2.16 Cr | 18.09% | 34.62% | 2.42x |
| FY25 | ₹45.23 Cr | 26.80% | ₹7.29 Cr | 24.84% | 31.90% | 0.97x |
| Jan-26 | ₹41.84 Cr | 24.72% | ₹5.75 Cr | 16.99% | 20.13% | 0.94x |
Why this IPO looks good
- Growing revenue and profit after tax in the last few financial years
- Strong EBITDA margin of 24.65% in the latest financial year
- Reasonable valuation with a price to earnings ratio of 14.61
Demand & Momentum
Subscription Trend (Times)
GMP Trend
GMP Trend (₹)
Documents
AI Research Q&A
Who is this IPO suitable for?
Ideal for investors who:
- Believe in India's regional industrial manufacturing expansion
- Have a medium to long-term investment horizon
- Are comfortable with moderate to high risk appetite